CN104093414A - 噬菌体的p3作为淀粉样蛋白结合剂的用途 - Google Patents

噬菌体的p3作为淀粉样蛋白结合剂的用途 Download PDF

Info

Publication number
CN104093414A
CN104093414A CN201280066659.6A CN201280066659A CN104093414A CN 104093414 A CN104093414 A CN 104093414A CN 201280066659 A CN201280066659 A CN 201280066659A CN 104093414 A CN104093414 A CN 104093414A
Authority
CN
China
Prior art keywords
amyloid
disease
domain
fusion rotein
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280066659.6A
Other languages
English (en)
Chinese (zh)
Inventor
R.克里什南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proclara Biosciences Inc
Original Assignee
NeuroPhage Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroPhage Pharmaceuticals Inc filed Critical NeuroPhage Pharmaceuticals Inc
Priority to CN202210423575.9A priority Critical patent/CN114748605A/zh
Publication of CN104093414A publication Critical patent/CN104093414A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
CN201280066659.6A 2011-11-29 2012-11-28 噬菌体的p3作为淀粉样蛋白结合剂的用途 Pending CN104093414A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210423575.9A CN114748605A (zh) 2011-11-29 2012-11-28 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564602P 2011-11-29 2011-11-29
US61/564,602 2011-11-29
US201261708709P 2012-10-02 2012-10-02
US61/708,709 2012-10-02
US201261730316P 2012-11-27 2012-11-27
US61/730,316 2012-11-27
PCT/US2012/066793 WO2013082114A1 (en) 2011-11-29 2012-11-28 Use of p3 of bacteriophage as amyloid binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210423575.9A Division CN114748605A (zh) 2011-11-29 2012-11-28 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途

Publications (1)

Publication Number Publication Date
CN104093414A true CN104093414A (zh) 2014-10-08

Family

ID=47326403

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280066659.6A Pending CN104093414A (zh) 2011-11-29 2012-11-28 噬菌体的p3作为淀粉样蛋白结合剂的用途
CN202210423575.9A Pending CN114748605A (zh) 2011-11-29 2012-11-28 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210423575.9A Pending CN114748605A (zh) 2011-11-29 2012-11-28 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途

Country Status (16)

Country Link
US (3) US9493515B2 (https=)
EP (1) EP2785364B1 (https=)
JP (2) JP6220344B2 (https=)
KR (1) KR20140100543A (https=)
CN (2) CN104093414A (https=)
AU (1) AU2012346056B2 (https=)
BR (1) BR112014013086A2 (https=)
CA (1) CA2857539C (https=)
EA (2) EA201792608A3 (https=)
IL (1) IL232867B (https=)
IN (1) IN2014CN04587A (https=)
MX (1) MX362175B (https=)
PH (1) PH12014501200A1 (https=)
SG (2) SG10201709849TA (https=)
WO (1) WO2013082114A1 (https=)
ZA (1) ZA201403863B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250154A (zh) * 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) * 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
WO2017091467A1 (en) * 2015-11-25 2017-06-01 Eli Lilly And Company Phage display vectors and methods of use
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102421210B1 (ko) * 2017-07-14 2022-07-18 지씨이 홀딩 에이비 전자 게이지
AU2023403257A1 (en) 2022-12-02 2025-06-12 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018685A2 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive fusionsproteine und verfahren zu ihrer herstellung
WO2006083795A1 (en) * 2005-02-01 2006-08-10 Ramot At Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
US20090105090A1 (en) * 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
WO2009143465A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
ATE484198T1 (de) 2002-08-20 2010-10-15 Sungene Gmbh & Co Kgaa Verwendung von astaxanthinhaltigen pflanzen oder pflanzenteilen der gattung tagetes als futtermittel
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
EP1991261A2 (en) 2006-02-15 2008-11-19 Ramot at Tel-Aviv University Ltd. Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007109733A2 (en) * 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
AU2007275258A1 (en) 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
KR101485202B1 (ko) 2006-10-11 2015-01-22 안티토페 리미티드 Ｔ 세포 에피토프 데이터베이스들
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
US20100113304A1 (en) * 2008-09-26 2010-05-06 Wyeth Compatible display vector systems
NZ592928A (en) * 2008-11-24 2012-12-21 Univ Ramot Method for treating parkinson' s disease using filamentous bacteriophage
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8856364B2 (en) 2011-03-11 2014-10-07 Google Inc. Conducting opportunistic network updates on a mobile device
WO2012125555A1 (en) 2011-03-11 2012-09-20 Ramot At Tel-Aviv University Ltd. Method for treating neurodegenerative tauopathy
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018685A2 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive fusionsproteine und verfahren zu ihrer herstellung
WO2006083795A1 (en) * 2005-02-01 2006-08-10 Ramot At Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
CN101166536A (zh) * 2005-02-01 2008-04-23 雷蒙特亚特特拉维夫大学有限公司 治疗与淀粉样蛋白沉积有关的炎症和涉及已活化小胶质细胞的脑部炎症的方法
US20090105090A1 (en) * 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
WO2009143465A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method of imaging abnormal deposits or plaques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. VIANELLI ET AL.: "Bacteriophage T4 Self-Assembly Localization of gp3 and Its Role in Determining Tail Length", 《JOURNAL OF BACTERIOLOGY》 *
ABRAHAM LIN ET AL.: "Inhibition of Bacterial Conjugation by Phage M13 and Its Protein g3p: Quantitative Analysis and Model", 《PLOS ONE》 *
BARBARA ECKERT: "Die Bedeutung der Stabilität und des Faltungsmechanismus des Gen-3-Proteins filamentöser Phagen für die Infektion von Escherichia coli", 《HTTPS://EPUB.UNI-BAYREUTH.DE/679/1/DISS_ECKERT.PDF》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250154A (zh) * 2014-12-03 2017-10-13 普罗克拉拉生物科学股份有限公司 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Also Published As

Publication number Publication date
US9493515B2 (en) 2016-11-15
SG10201709849TA (en) 2017-12-28
PH12014501200B1 (en) 2014-09-08
EA029602B1 (ru) 2018-04-30
SG11201402425TA (en) 2014-06-27
JP2015505823A (ja) 2015-02-26
IL232867B (en) 2019-12-31
JP6440765B2 (ja) 2018-12-19
ZA201403863B (en) 2019-03-27
WO2013082114A1 (en) 2013-06-06
EA201792608A3 (ru) 2018-08-31
CN114748605A (zh) 2022-07-15
MX362175B (es) 2019-01-07
CA2857539A1 (en) 2013-06-06
EA201792608A2 (ru) 2018-04-30
EA201491063A1 (ru) 2015-02-27
US10151762B2 (en) 2018-12-11
KR20140100543A (ko) 2014-08-14
EP2785364A1 (en) 2014-10-08
PH12014501200A1 (en) 2014-09-08
AU2012346056B2 (en) 2018-02-22
JP6220344B2 (ja) 2017-10-25
MX2014006337A (es) 2016-02-10
JP2017122124A (ja) 2017-07-13
US20170115311A1 (en) 2017-04-27
US20140335016A1 (en) 2014-11-13
US20160009766A1 (en) 2016-01-14
BR112014013086A2 (pt) 2020-10-27
AU2012346056A1 (en) 2014-07-03
US9493516B2 (en) 2016-11-15
IL232867A0 (en) 2014-07-31
IN2014CN04587A (https=) 2015-09-18
CA2857539C (en) 2021-08-03
EP2785364B1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
US10151762B2 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
US10526377B2 (en) Fusion proteins comprising P3 of bacteriophage
JP2021527407A (ja) 全般的アミロイド相互作用モチーフ（ｇａｉｍ）
HK1197655B (en) Use of p3 of bacteriophage as amyloid binding agents
HK1197655A (en) Use of p3 of bacteriophage as amyloid binding agents
CA3102841C (en) General amyloid interaction motif (gaim)
HK1213775B (en) Use of p3 of bacteriophage fusion proteins as amyloid binding agents
RS56559B1 (sr) Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Clara Biosciences Limited by Share Ltd

Address before: Massachusetts, USA

Applicant before: NEUROPHAGE PHARMACEUTICALS, INC.

CB02 Change of applicant information